BT-13 is a potent and selective glial cell line-derived neurotrophic factor (GDNF) receptor RET agonist independently of GFLs, promoting neurite growth from sensory neurons in vitro and attenuates experimental neuropathy in the Rat
In Vitro
BT-13 stimulates phosphorylation of RET, as well as RET-dependent intracellular signaling, but activated neither NGF receptor TrkA nor BDNF receptor TrkB nor intracellular signaling in the absence of RET. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
BT-13 (20 and 25mg/kg in rats induced by ligation of left L5 and L6 spinal nerves) has a slight antinociceptive/antihyperalgesic effect and protected DRG neurons in rats with surgery-induced neuropathy . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rats induced by ligation of left L5 and L6 spinal nerves . Dosage: 5-25 mg/kg, dissolved in sesame oil containing 5% DMSO. Administration: Subcutaneous injections on post-surgical day 1, 3, 5, 8, 10, and 12. Result: 20 and 25mg/kg decreased mechanical hypersensitivity and normalized expression of sensory neuron markers in dorsal root ganglia.
